TY - JOUR
T1 - Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases
T2 - Retrospective Case Series
AU - Braga Neto, Manuel B.
AU - Ramos, Guilherme P.
AU - Loftus, Edward V.
AU - Faubion, William A.
AU - Raffals, Laura E.
PY - 2021/6
Y1 - 2021/6
N2 - The etiology of inflammatory bowel disease (IBD) has yet to be fully understood; however, it is thought to be a result of genetic, immunologic, and environmental factors, including changes in the gut microbiome.1,2 Immune checkpoint inhibitors (ICI) have revolutionized treatment of advanced cancer. They activate the immune system by promoting cytotoxic T-cell survival and antitumor effects. A total of 7 ICIs currently are approved by the United States Food and Drug Administration, and target cytotoxic T lymphocyte–associated protein 4 (ipilimumab); anti–programmed cell death 1 (PD-1) (nivolumab, pembrolizumab, and cemiplimab), or anti–PD-ligand 1 (atezolizumab, durvalumab, and avelumab). However, by activating the immune system, these medications also can lead to off-target inflammation and autoimmunity, including ICI-induced colitis, which has been reported in up to 13.6% of patients.3
AB - The etiology of inflammatory bowel disease (IBD) has yet to be fully understood; however, it is thought to be a result of genetic, immunologic, and environmental factors, including changes in the gut microbiome.1,2 Immune checkpoint inhibitors (ICI) have revolutionized treatment of advanced cancer. They activate the immune system by promoting cytotoxic T-cell survival and antitumor effects. A total of 7 ICIs currently are approved by the United States Food and Drug Administration, and target cytotoxic T lymphocyte–associated protein 4 (ipilimumab); anti–programmed cell death 1 (PD-1) (nivolumab, pembrolizumab, and cemiplimab), or anti–PD-ligand 1 (atezolizumab, durvalumab, and avelumab). However, by activating the immune system, these medications also can lead to off-target inflammation and autoimmunity, including ICI-induced colitis, which has been reported in up to 13.6% of patients.3
UR - http://www.scopus.com/inward/record.url?scp=85088284027&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088284027&partnerID=8YFLogxK
U2 - 10.1016/j.cgh.2020.06.031
DO - 10.1016/j.cgh.2020.06.031
M3 - Short survey
C2 - 32565289
AN - SCOPUS:85088284027
SN - 1542-3565
VL - 19
SP - 1285-1287.e1
JO - Clinical Gastroenterology and Hepatology
JF - Clinical Gastroenterology and Hepatology
IS - 6
ER -